Conjugation Process Development and Scale-Up
Authors:
- 1 July 2013
- book chapter
- Published by Springer Nature
- Vol. 1045, 235-248
Abstract
Manufacturing highly potent antibody–drug conjugates (ADCs) is a demanding task—combining conventional organic synthesis with biotechnological manufacturing. Hence a series of new and unique engineering and chemistry challenges have to be addressed to support clinical trials and commercial manufacturing. These include the development of reliable processes leading to uniform product properties, as well as establishment of ADC-specific analytical methods and safe strategies for handling cytotoxic compounds. This review focuses on process development and scale-up for the production of ADCs and highlights the most important features in such a process.Keywords
This publication has 13 references indexed in Scilit:
- Technology trends in antibody purificationJournal of Chromatography A, 2012
- Targeted Drug Delivery Using ImmunoconjugatesJournal of Immunotherapy, 2011
- Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug ConjugatesCancer Research, 2011
- Investigational antibody-drug conjugates for hematological malignanciesExpert Opinion on Investigational Drugs, 2010
- Antibody–drug conjugates for cancer: poised to deliver?Nature Reviews Drug Discovery, 2010
- Current Trends in Monoclonal Antibody Development and Manufacturing2010
- Engineered anti-CD70 antibody-drug conjugate with increased therapeutic indexMolecular Cancer Therapeutics, 2008
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic DrugsAccounts of Chemical Research, 2007
- Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug ConjugateClinical Cancer Research, 2004
- The Thermal Stability of Immunoglobulin: Unfolding and Aggregation of a Multi-Domain ProteinBiophysical Journal, 2000